418 related articles for article (PubMed ID: 16315314)
41. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
42. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
43. CMV in kidney transplantation: a single center experience over 22 years.
Nashan B; Lück R; Kliem V; Brunkhorst R; Schlitt HJ; Klempnauer J
Clin Transpl; 1999; ():181-8. PubMed ID: 11038636
[TBL] [Abstract][Full Text] [Related]
44. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
45. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation.
Malaise J; Ricart MJ; Moreno A; Crespo M; Fernández-Cruz L; Van Ophem D; Squifflet JP;
Transplant Proc; 2005; 37(6):2848-50. PubMed ID: 16182830
[TBL] [Abstract][Full Text] [Related]
46. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
Prian GW; Koep LJ
Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
[No Abstract] [Full Text] [Related]
47. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
48. Gancyclovir prophylaxis in high risk patients.
Campino A
Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
[TBL] [Abstract][Full Text] [Related]
49. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
50. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection.
Kranz B; Vester U; Wingen AM; Nadalin S; Paul A; Broelsch CE; Hoyer PF
Pediatr Transplant; 2008 Jun; 12(4):474-8. PubMed ID: 18466436
[TBL] [Abstract][Full Text] [Related]
51. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD
Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594
[TBL] [Abstract][Full Text] [Related]
52. Impact of cytomegalovirus match on survival after cardiac and lung transplantation.
Bonatti H; Tabarelli W; Ruttmann E; Kafka R; Larcher C; Höfer D; Klaus A; Laufer G; Geltner C; Margreiter R; Müller L; Antretter H
Am Surg; 2004 Aug; 70(8):710-4. PubMed ID: 15328806
[TBL] [Abstract][Full Text] [Related]
53. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
54. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
55. [The significance of risk-adapted antiviral prophylaxis and modern viral diagnosis for organ survival after kidney transplantation].
Bach D; Will A; Grabensee B; Krempe C
Dtsch Med Wochenschr; 1997 Oct; 122(43):1334. PubMed ID: 9410702
[No Abstract] [Full Text] [Related]
56. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients.
Das A
Hepatology; 2000 Feb; 31(2):311-7. PubMed ID: 10655251
[TBL] [Abstract][Full Text] [Related]
58. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
59. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
60. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
